This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kelly, K. Search for Related Content PubMed PubMed Citation Articles by Kelly, K.

The Role of Targeted Agents in Adjuvant Therapy for Non–Small Cell Lung Cancer

Authors' Affiliation: University of Colorado Health Sciences Center, Denver, Colorado

Requests for reprints: Karen L. Kelly, University of Colorado Health Sciences Center, P.O. Box 6511, Aurora, CO 80010. Phone: 303-724-3903; Fax: 303-724-3115; E-mail: karen.kelly{at}uchsc.edu.

The recent survival benefit of adjuvant chemotherapy in early stage non–small cell lung cancer provides optimism for the future success of targeted therapy in this setting. It is important that we begin to explore molecularly targeted agents in the adjuvant arena, but how best to accomplish this in the face of these new findings presents a challenge. Criteria for selecting promising targeted therapies and optimal trial designs to evaluate them expeditiously in the adjuvant setting are clearly needed.

This article has been cited by other articles:

				Y.-L. Hsu, C.-Y. Cho, P.-L. Kuo, Y.-T. Huang, and C.-C. Lin Plumbagin (5-Hydroxy-2-methyl-1,4-naphthoquinone) Induces Apoptosis and Cell Cycle Arrest in A549 Cells through p53 Accumulation via c-Jun NH2-Terminal Kinase-Mediated Phosphorylation at Serine 15 in Vitro and in Vivo J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 484 - 494. [Abstract] [Full Text] [PDF]